Aktiesnakken — August 2011
-
Jo, gift og at være gift har visse ligheder
-
Og hvilken kurs har du købt dem til?
-
-
Novozymes producerer fin vækst både i omsætning og profit, men den er meget dyr i forhold til C20-aktier generelt. Derfor skal de holde samme vækst i en årrække frem hvis ikke den skal få samme hug som den gjorde til regnskabet forleden.
-
Og jeg er value-investor, hvis du søger tips på den tilgang
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

